Agenda
Please check back for the most updated agenda.
June 23rd – Patient Advocate Orientation
Basic tools and information for patients and advocates to make the most of the scientific sessions of the International ILC Virtual Symposium and learn about lobular breast cancer. Everyone is welcome to attend.
12:00 – 1:30pm EST
Moderator: Siobhán Freeney, Founding member Lobular Ireland; Patient Advocate, European Lobular Breast Cancer Consortium (ELBCC)
Karen Van Baelen, MD, KU Leuven, UZ Leuven, Leuven, Belgium: “Lobular Breast Cancer: from diagnosis to treatment”
Christine Desmedt, PhD, KU Leuven, Leuven, Belgium : “The ABCs of Cancer Biology”
Steffi Oesterreich, PhD, UPMC Hillman Cancer Center, Magee Womens Research Institute, University of Pittsburgh, Pittsburgh, PA: “Peculiarities of Lobular Breast Cancer Biology”
June 24th – Day 1 of the International ILC Virtual Symposium Scientific Sessions
Keynote Address
Christine Desmedt, PhD, Katholieke Universiteit, Leuven
“Molecular features of lobular breast cancer: opportunities for individualizing therapy“
9:00am – 10:00am EST
Presentations and Q&A: Addressing Challenges in ILC Pathology, Diagnosis and Imaging
Chair: Steffi Oesterreich, PhD, UPMC Hillman Cancer Center, Magee Womens Research Institute, University of Pittsburgh, Pittsburgh, PA
10:00am – 12:00pm EST
10:00am
Matthias Christgen, MD, Medizinische Hochschule Hannover, Hannover, Germany
“Lobular Breast Cancer: Histomorphology and different concepts of a special spectrum of tumors“
10:30am
Peter Simpson, PhD, University of Queensland, Australia
“Developing Lobsig – a signature capturing the molecular heterogeneity of ILC“
11:00am
Jorge Reis-Filho, MD, Memorial Sloan Kettering Cancer Center, NYC
“Artificial intelligence in breast pathology: beyond cancer detection“
11:30am
Hannah Linden, MD, Seattle Cancer Alliance, Seattle, WA
“Imaging challenges in ILC and molecular imaging advances“
Break
12:00pm – 12:30pm
Presentations and Q&A: Addressing Challenges in ILC Treatment
Chair: Otto Metzger, MD, Dana-Farber Cancer Institute, Harvard Medical School. Boston, MA
12:30pm – 2:30pm EST
12:30pm
Sabine Linn, MD, PhD, Netherlands Cancer Institute, Netherlands
“Treatment of early-stage ILC. What is different?“
1:00pm
Rinath Jeselsohn, MD, Dana Farber-Cancer Institute, Boston, MA
“Estrogen signaling – what are the differences between lobular and ductal cancer?“
1:30pm
Ron Bose, MD, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
“Targeted anti-HER2 based therapy? Her2 mutations and treatment rationale“
2:00pm
Otto Metzger, MD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
“Discussion with breast cancer advocates on current and future aspect of ILC tailored therapies“
June 25th – Day 2 of the International ILC Virtual Symposium Scientific Sessions
Panel Discussion with Q&A: How researchers, clinicians and patient advocates can accelerate lobular breast cancer research
Leigh Pate, Founder Lobular Breast Cancer Alliance
Steffi Oesterreich, PhD, UPMC Hillman Cancer Center, Magee Womens Research Institute, University of Pittsburgh, Pittsburgh, PA
Laurie Hutcheson, Executive Director, Lobular Breast Cancer Alliance
Siobhán Freeney, Founding member Lobular Ireland; Patient Advocate, European Breast Cancer Consortium (ELBCC)
Claire Turner, Founder and Chair, Lobular Breast Cancer UK, UK Patient Advocate Representative for European Lobular Breast Cancer Consortium
9:00am – 10:00am EST
Presentations and Q&A: New Avenues in ILC Research
Chair: Patrick Derksen, PhD, UMC Utrecht (Universitair Medisch Centrum Utrecht), The Netherland
10:00am – 12:00pm EST
10:00am
Matthew Sikora, PhD, University of Colorado Cancer Center, Aurora, CO
“Understanding ILC as a unique context for interaction between estrogen signaling and DNA damage response“
10:40am
George Sflomos, PhD, Swiss Institute for Experimental Cancer Research, Lausanne, Switzerland
“Novel Models of Lobular Breast Cancers: what we have learned and where we are heading“
11:20am
Yeji An, University of Toronto, Toronto, Canada
“Refining the ILC mouse model: exploring the role of 16q hemizygosity in breast cancer“
Break
12:00pm – 12:30pm
Presentations and Q&A: Lobular Breast Cancer Biology
Chair: Christine Desmedt, PhD, Katholieke Universiteit, Leuven
12:30pm – 2:00pm EST
12:30pm
Val Brunton, PhD, Cancer Research UK Edinburgh Centre, Edinburgh
“Tumor-stromal interactions in ILC“
1:00pm
Adrian Lee, PhD, UPMC Hillman Cancer, Institute for Precision Medicine, University of Pittsburgh, Pittsburgh, PA
“Single-Cell transcriptomic heterogeneity in invasive ductal and lobular breast cancer cells“
1:30pm
Patrick Derksen, PhD, UMC Utrecht, The Netherland
“Oncogene addiction 2.0. E-cadherin loss causes vulnerabilities to targeted treatments“
2:00pm
Clare Isacke, PhD, The Institute of Cancer Research, London
“Characterization and modeling of lobular breast cancer leptomeningeal metastasis“
June 30th – Highlights of the International ILC Virtual Symposium
Join leading lobular breast cancer researchers and ILC advocates for a discussion of the highlights of the International ILC Virtual Symposium and Q&A. The highlights session is open to everyone, but is tailored for patients and patient advocates.
12:00 – 1:30pm EST
Moderator: Laurie Hutcheson, Executive Director, Lobular Breast Cancer Alliance
Rachel C. Jankowitz, MD, Associate Professor of Clinical Medicine in the Division of Hematology/Oncology at the Perelman School of Medicine at the University of Pennsylvania, and Director of the Rena Rowan Breast Center at the Penn Abramson Cancer Center
Matthew J. Sikora, PhD, Assistant Professor of Pathology at the University of Colorado Anschutz Medical Campus
Gary A. Ulaner, MD, PhD, Chair of Molecular Imaging and Therapy at Hoag Family Cancer Institute